Traveler's Diarrhea Treatment Market

1. Traveler's Diarrhea Treatment Market ● ● Every year approximately around 10 million US citizens are affected by traveler’s diarrhea. Among the EU5 countries, Germany had the highest percentage of diagnosed traveler’s diarrhea incident population in 2017 followed by italy. Traveler diarrhea is a benign self illness lasting 3 to 5 day, the mean time period for traveler diarrhea is 3.6 days. ● As per DelveInsight, the incident population of Traveler's Diarrhea (TD) was estimated to be 41,611,405 in 7 major markets in 2018. The United States accounts for the highest TD cases (16,964,730 in 2018), followed by EU5 (Germany, France, Italy, Spain and UK) and Japan. Traveler's diarrhea (TD) is a digestive tract disorder accompanied by at least 1 of the following diseases and symptoms like fever, nausea, vomiting, cramps, tenesmus, or bloody stools (dysentery). It mainly occurs when a person travels from a developed nation to less developed or developing countries. Traveler diarrhea is a benign self illness lasting 3 to 5 day, the mean time period for traveler diarrhea is 3.6 days. Poor hygiene in developing countries is usually the main factor for Traveler's Diarrhea . Classic travelers' diarrhea is defined as at least three loose to watery stools in 24 hours with or without one or more symptoms of abdominal cramps, fever, nausea, vomiting, or blood in the stool. Mild to moderate diarrhea is one or two loose stools in 24 hours with or without another enteric symptom. The median time to onset is six or seven days after arrival. Although the diarrhea often resolves spontaneously over three or four days, up to a quarter of affected travelers need to alter their plans, interrupting their holiday or business activities. DelveInsight's ' Traveler's Diarrhea Market report provides Traveler's Diarrhea Insights, Epidemiology and Market Forecast till 2028'. The report also delivers an in-depth understanding of the Traveler's Diarrhea in terms of market size, historical and forecasted epidemiology as well as the market trends in the EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan and the United States,. The key companies in Traveler's Diarrhea market includes:Procter and Gamble, Scandinavian Biopharma, Cosmo Pharmaceuticals, Salix Pharmaceuticals Visit for Traveler's Diarrhea Sample Page: https://www.delveinsight.com/report-store/traveler-s-diarrhea-market-insights-epidemiology-and- market-forecast Traveler's diarrhea Diagnosis and treatment Marketed drugs for traveler's diarrhea include Aemcolo (rifamycin, Cosmo Pharmaceuticals), Xifaxan (rifaximin, Salix Pharmaceuticals).

2. Delveinsight’s Traveler's Diarrhea (TD) Report Insights • Patient Population • Therapeutic Approaches • Pipeline Analysis • Market Size and Trends • Market Opportunities • Impact of upcoming Therapies Delveinsight’s Traveler's Diarrhea (TD) Report Key Strengths • 10 Year Forecast • 7MM Coverage • Epidemiology Segmentation • Drugs Uptake • Highly Analyzed Market • Key Cross Competition Delveinsight’s Traveler's Diarrhea (TD) Report Assessment • Current Treatment Practices • Unmet Needs • Detailed Pipeline Product Profiles • Market Attractiveness • Market Drivers and Barriers Key Benefits of Delveinsight’s Traveler's Diarrhea Report The Delveinsight’s Traveler's Diarrhea Report will assist Business to develop their Strategies by understanding the Traveler's Diarrhea trends and forecasts that will shape and drive the Traveler's Diarrhea (TD) market in coming years. The report also provides Traveler's Diarrhea future market competition. Visit for more information: https://www.delveinsight.com/report-store/traveler-s-diarrhea-market-insights-epidemiology-and- market-forecast Source: Delveinsight #TravelersDiarrhea, #Diarrhea #travelvaccines, #travelhealth #health #biotech #pharma